Burzynski Research Institute INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
Burzynski Research Institute reports its fiscal year 2025 results, highlighting ongoing research and development efforts despite a full clinical hold on its IND 43742.
OTC.Pink
Burzynski Research Institute's annual report reveals ongoing research and development efforts, funded by its majority shareholder, while facing a full clinical hold on its key drug trials.